Hartaj Singh is a Founding Partner of Tecumseh Partners, advising biotech companies on valuation, strategy, and investor engagement. He also writes The Biotech Capital Compass, a newsletter focused on biotech market trends. Mr. Singh’s 30+ year career spans biotech equity research, hedge fund investing, and consulting — previously at firms like Oppenheimer, BTIG and Lehman Brothers. With an MBA from Duke and a background in computational neurobiology, Mr. Singh brings a science-driven approach to biotech investing.
U.S Commercial-Stage Biotechs Positioned to Do Well as Tariff Fears Ease
April 29, 2025
